GLP-3 RTA [Triple G] 10mg. Used to support weight management, appetite control, reduced food cravings, and metabolic health. Lab tested, discreetly shipped across Canada.
FormatLyophilized Vial
ConcentrationDepends on reconstitution with BAC water
Pack Size Selected: 5 Pack
Pay with Interac e-Transfer or Crypto
HPLC verified. COA on file for this batch
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
GLP-3 RTA (Triple G) is a triple incretin receptor agonist simultaneously targeting glucagon like peptide 1 (GLP-1), glucose dependent insulinotropic polypeptide (GIP), and glucagon receptors. The most advanced incretin based research compound in CSD’s metabolic peptide range. Hudson Science’s standalone 10mg lyophilized vial delivers the lowest concentration single unit GLP-3 RTA presentation in CSD’s range: distinct from the Hudson Science 10mg 5 pack in that it provides a single individually sealed vial suited to researchers requiring a one time evaluation unit, a supplementary vial to extend an existing protocol, or initial compound assessment before committing to multi vial or higher concentration supply options.
The standalone 10mg single vial occupies a specific position in CSD’s GLP-3 RTA format hierarchy that the 5 pack does not fill. Where the 5 pack provides five individually sealed 10mg vials suited to extended low dose protocols requiring multiple sequential administrations from matched compound batches, the single vial supports one time or limited administration research designs, comparative studies requiring a defined single unit compound source, or procurement decisions where minimizing initial compound commitment is a priority before progressing to larger supply volumes across the concentration ladder.
The triple receptor mechanism remains consistent across all GLP-3 RTA presentations. GLP-1 receptor activation drives glucose dependent insulin secretion, glucagon suppression, and central nervous system satiety signaling. GIP receptor activation contributes complementary insulinotropic activity alongside adipose tissue metabolic and bone turnover research dimensions. Glucagon receptor co activation adds hepatic glucose output regulation, thermogenic energy expenditure stimulation through brown adipose tissue activation, and lipolytic activity. Producing a synergistic metabolic response that distinguishes triple incretin agonism from the dual GIP/GLP-1 mechanism of CSD’s GLP-2 TRZ and GLP-2 TZ listings and the pure GLP-1 selectivity of the Semaglutide pen.
Hudson Science formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s GLP-3 RTA range now spans the most comprehensive incretin agonist format and concentration selection in our catalogue: single vials from 10mg through 60mg, a 5 pack multi unit format, and adjustable dose pens at 16mg and 40mg across Hudson Science, iLab Pharma, and F40 Biotech. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.
Commonly researched alongside dual incretin agonist compounds and Semaglutide in comparative receptor pathway and metabolic activity studies. Browse CSD’s full peptide range for complete sourcing.
So far so good. Only been a couple weeks and noticing weight loss
★★★★★TeresaVerified buyer2026-07-26
Great effective product. Super fast delivery.
★★★★★Ashley K.Verified buyer2026-07-22
Works great! Have been a returning customer almost a year
★★★★★MelVerified buyer2026-06-26
Great product. Easy to use with minimal side effects.
★★★★★Hamed GholipourVerified buyer2026-02-09
Amazing product with amazing results
★★★★★AnonymousVerified buyer2025-12-16
This stuff is awesome! Started at 500mcg a week, then up to 1mg. It's cut out all the food noise, with no real side effects and I'm dropping the belly fat I recently gained from disability awaiting surgery. I did bump it up to 2mg for a week, but found I was eating too little and became a bit hypoglycemic with low energy. 1mg/week seems to be best for me at the moment.
GLP-3 RTA contains 10mg of RTA, an investigational peptide commonly described as a Triple G receptor agonist. RTA simultaneously activates GIP, GLP-1, and glucagon receptors. Research has focused on body weight regulation, appetite signaling, glucose metabolism, insulin sensitivity, energy expenditure, lipid metabolism, and broader cardiometabolic function.
RTA is called Triple G because it activates three metabolic hormone receptor systems: glucose dependent insulinotropic polypeptide (GIP), glucagon like peptide 1 (GLP-1), and glucagon. GIP and GLP-1 signaling participate in glucose regulation, insulin response, and appetite related pathways, while glucagon receptor activation contributes additional metabolic and energy expenditure signaling. This three receptor profile is the defining feature of RTA.
The primary difference is receptor activity. Semaglutide primarily activates the GLP-1 receptor, while tirzepatide activates both GIP and GLP-1 receptors. RTA adds glucagon receptor agonism to GIP and GLP-1 activity, creating a triple receptor mechanism. This additional pathway gives RTA a distinct research profile involving energy expenditure, hepatic metabolism, lipid metabolism, appetite regulation, and glucose control.
RTA is being investigated extensively in human clinical research involving obesity, body weight regulation, type 2 diabetes, glycemic control, and cardiometabolic health. Studies have also examined appetite, insulin sensitivity, lipid metabolism, and other metabolic outcomes. Its combined GIP, GLP-1, and glucagon receptor activity is designed to influence multiple complementary pathways involved in energy intake, glucose regulation, and energy expenditure.
Yes! This batch is HPLC tested to verify RTA identity and content accuracy at 10mg per vial. A certificate of analysis is available.
![GLP-3 RTA [Triple G] - 10mg](https://www.canadasteroiddepot.is/wp-content/uploads/2024/10/HUD-GLP3-10-600x600.webp)
![GLP-3 RTA [Triple G] - 10mg](https://www.canadasteroiddepot.is/wp-content/uploads/2024/10/HUD-GLP3-10-100x100.webp)